Our synovial sarcoma nomogram is a tool designed to predict the likelihood of surviving three years and five years after being diagnosed with synovial sarcoma, based on clinical and pathologic factors known before surgery. This tool is not designed for patients who received chemotherapy with anthracycline and ifosfamide (AI) before or shortly after surgery, as the nomogram predictions may be inaccurate.
Results produced by this tool are based on data from patients treated at MSK, a large research institution with surgeons who perform a high volume of synovial sarcoma procedures. All results must be understood in the context of each patient’s specific treatment plan. Patients and caregivers using this tool should discuss the result with the patient’s physician.
To gather the information required to use this nomogram, use our worksheet.